EP4126199A4 - Method for treatment of neurological disorders using synaptic pathway training - Google Patents

Method for treatment of neurological disorders using synaptic pathway training Download PDF

Info

Publication number: EP4126199A4
Authority: EP; European Patent Office
Prior art keywords: treatment; neurological disorders; synaptic pathway; training; pathway training
Prior art date: 2020-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21776197.2A

Other languages

German (de)

French (fr)

Other versions

EP4126199A1 (en

Inventor

Joseph Rustick

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-03-23

Filing date

2021-03-16

Publication date

2024-04-10

2020-03-23 Priority claimed from US16/827,546 external-priority patent/US20200222656A1/en

2021-03-16 Application filed by Individual filed Critical Individual

2023-02-08 Publication of EP4126199A1 publication Critical patent/EP4126199A1/en

2024-04-10 Publication of EP4126199A4 publication Critical patent/EP4126199A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Radiology & Medical Imaging (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Social Psychology (AREA)
Developmental Disabilities (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

EP21776197.2A 2020-03-23 2021-03-16 Method for treatment of neurological disorders using synaptic pathway training Pending EP4126199A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16/827,546 US20200222656A1 (en)	2016-10-18	2020-03-23	Method for treatment of depression using synaptic pathway training
PCT/US2021/022517 WO2021194796A1 (en)	2020-03-23	2021-03-16	Method for treatment of neurological disorders using synaptic pathway training

Publications (2)

Publication Number	Publication Date
EP4126199A1 EP4126199A1 (en)	2023-02-08
EP4126199A4 true EP4126199A4 (en)	2024-04-10

Family

ID=77890584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21776197.2A Pending EP4126199A4 (en)	2020-03-23	2021-03-16	Method for treatment of neurological disorders using synaptic pathway training

Country Status (7)

Country	Link
EP (1)	EP4126199A4 (en)
BR (1)	BR112022019234A2 (en)
CA (1)	CA3172981A1 (en)
IL (1)	IL296693A (en)
MX (1)	MX2022011862A (en)
WO (1)	WO2021194796A1 (en)
ZA (1)	ZA202210356B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4486448A1 (en)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016061320A2 (en) *	2014-10-15	2016-04-21	Rowan University	Timber therapy for post-traumatic stress disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9064036B2 (en) *	2008-04-24	2015-06-23	The Invention Science Fund I, Llc	Methods and systems for monitoring bioactive agent use
WO2016004396A1 (en) *	2014-07-02	2016-01-07	Christopher Decharms	Technologies for brain exercise training
WO2017180589A1 (en) *	2016-04-11	2017-10-19	Auspex Pharmaceuticals, Inc.	Deuterated ketamine derivatives
US10596378B2 (en) *	2016-10-18	2020-03-24	Joseph Rustick	Method for treatment of depression using synaptic pathway training
US20200222656A1 (en) *	2016-10-18	2020-07-16	Joseph Rustick	Method for treatment of depression using synaptic pathway training
US11426367B2 (en) *	2018-05-04	2022-08-30	Perception Neuroscience, Inc.	Methods of treating substance abuse

2021
- 2021-03-16 BR BR112022019234A patent/BR112022019234A2/en unknown
- 2021-03-16 CA CA3172981A patent/CA3172981A1/en active Pending
- 2021-03-16 IL IL296693A patent/IL296693A/en unknown
- 2021-03-16 MX MX2022011862A patent/MX2022011862A/en unknown
- 2021-03-16 WO PCT/US2021/022517 patent/WO2021194796A1/en not_active Ceased
- 2021-03-16 EP EP21776197.2A patent/EP4126199A4/en active Pending
2022
- 2022-09-19 ZA ZA2022/10356A patent/ZA202210356B/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016061320A2 (en) *	2014-10-15	2016-04-21	Rowan University	Timber therapy for post-traumatic stress disorder

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAKWAR ELIAS ET AL: "A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial", AMERICAN JOURNAL OF PSYCHIATRY., vol. 177, no. 2, 1 February 2020 (2020-02-01), US, pages 125 - 133, XP093136303, ISSN: 0002-953X, DOI: 10.1176/appi.ajp.2019.19070684 *
KRYSTAL JOHN H ET AL: "Ketamine: A Paradigm Shift for Depression Research and Treatment", NEURON, vol. 101, no. 5, 6 March 2019 (2019-03-06), pages 774 - 778, XP085620115, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2019.02.005 *
See also references of WO2021194796A1 *

Also Published As

Publication number	Publication date
IL296693A (en)	2022-11-01
BR112022019234A2 (en)	2022-11-08
MX2022011862A (en)	2023-02-16
ZA202210356B (en)	2023-02-22
EP4126199A1 (en)	2023-02-08
CA3172981A1 (en)	2021-09-30
WO2021194796A1 (en)	2021-09-30

Publication	Publication Date	Title
EP4010072A4 (en)	2023-03-29	Treatment of central nervous system disorders
EP4452331B8 (en)	2025-09-17	Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
AU2021381324A9 (en)	2024-10-24	Methods of treating diseases and disorders
AU2022233762A1 (en)	2023-10-05	Method of treating diseases using gremlin1 antagonists
ZA202400405B (en)	2025-03-26	Methods of treating neurological diseases
EP4126199A4 (en)	2024-04-10	Method for treatment of neurological disorders using synaptic pathway training
EP4135661A4 (en)	2024-07-10	Compositions and methods for treatment of neurological disorders
EP4267196A4 (en)	2024-03-20	Treatment of neurological diseases
IL321201A (en)	2025-07-01	Methods of treating neurological disorders
IL319571A (en)	2025-05-01	R-trihexyphenidyl for treatment of movement disorders
CA3269248A1 (en)	2024-04-04	Compositions and methods for treatment of neurological disorders
HK40117579A (en)	2025-05-16	Methods of treating neurological disorders
HK40113386A (en)	2025-02-14	Treatment of neurological disorders
EP4229035A4 (en)	2024-07-31	Intranasal administration of suramin for treating nervous system disorders
HK40109636A (en)	2024-12-06	Methods of treating neurological diseases
HK40109637A (en)	2024-12-06	Methods of treating neurological diseases
EP4395884A4 (en)	2025-04-09	Machine learning for treatment of physiological disorders
HK40087367A (en)	2023-09-08	Compositions and methods for treatment of neurological disorders
HK40121519A (en)	2025-09-12	Methods of treating neurological diseases
AU2022902914A0 (en)	2022-10-20	Methods for treating paediatric neurological disorders
HK40097523A (en)	2024-03-15	Methods of treating eye disorders
HK40119488A (en)	2025-07-18	Compositions and methods for treatment of neurological disorders
HK40108375A (en)	2024-11-08	Methods of treating mitochondria-related disorders
HK40116208A (en)	2025-04-17	Methods of treating metabolic disorders
HK40123266A (en)	2025-10-17	Methods for the treatment of neurodegenerative disorders

Legal Events

Date	Code	Title	Description
2021-10-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-01-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-01-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-02-08	17P	Request for examination filed	Effective date: 20221017
2023-02-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-06-28	DAV	Request for validation of the european patent (deleted)
2023-06-28	DAX	Request for extension of the european patent (deleted)
2024-03-06	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61N0001360000 Ipc: A61K0031135000
2024-04-10	A4	Supplementary search report drawn up and despatched	Effective date: 20240313
2024-04-10	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/30 20060101ALI20240306BHEP Ipc: A61P 25/24 20060101ALI20240306BHEP Ipc: A61P 25/26 20060101ALI20240306BHEP Ipc: A61P 25/00 20060101ALI20240306BHEP Ipc: A61N 1/36 20060101ALI20240306BHEP Ipc: A61K 45/06 20060101ALI20240306BHEP Ipc: A61K 31/135 20060101AFI20240306BHEP